Myogene Bio, LLC
Publicly observedSan Diego, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | San Diego | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Myogene Bio, LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | KEESEUSBQWL7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2025Publicly observed
NIH SBIR/STTR award: Advancing manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophy
USD 498,365.00 · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2025Publicly observed
NIH SBIR/STTR award: Advancing manufacturing and release testing of a gene editing therapy for Duchenne muscular dystrophy
USD 499,300.00 · National Institute of Arthritis and Musculoskeletal and Skin Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2019Publicly observed
NIH SBIR/STTR award: Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy
USD 978,397.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2019Publicly observed
NIH SBIR/STTR award: Further assessment of durability of a gene editing therapy for Duchenne muscular dystrophy
USD 1,321,604.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.